Trials / Terminated
TerminatedNCT01287338
A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
A Randomized, Double-Masked, Placebo-Controlled, Proof of Concept Study to Evaluate the Short-term Safety and Efficacy of the QLT Proprietary Olopatadine Punctal Plug Delivery System in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 143 (actual)
- Sponsor
- Mati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test if olopatadine punctal plugs can reduce the symptoms (itching) of allergic conjunctivitis to ragweed in an Environmental Exposure Chamber model.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olopatadine | low dose |
| DRUG | Olopatadine | high dose |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2011-02-01
- Last updated
- 2013-09-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01287338. Inclusion in this directory is not an endorsement.